Literature DB >> 16869121

Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.

Emad A Salem1, Muammer Kendirci, Wayne J G Hellstrom.   

Abstract

Udenafil is an oral PDE5 inhibitor that is currently available in South Korea for the treatment of erectile dysfunction (ED). Phase II clinical data presented at the 11th World Congress of the International Society for the Sexual and Impotence Research showed that in men with mild-to-severe ED, the drug produced a significant improvement in erectile function after 12 weeks of treatment. Udenafil has been reported as being well tolerated, although in August 2005, the Korean Food & Drug Administration had demanded further details regarding the presence of carcinogenic substances in the drug. A phase IIa clinical trial for ED is currently underway in the US, and phase III trials are planned for 2006.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16869121

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  13 in total

1.  Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy.

Authors:  T-H Kim; Y-S Ha; S H Choi; E S Yoo; B W Kim; S-J Yun; W-J Kim; Y S Kwon; T G Kwon
Journal:  Int J Impot Res       Date:  2015-10-29       Impact factor: 2.896

Review 2.  Prevalence and medical management of erectile dysfunction in Asia.

Authors:  Kwangsung Park; Eu Chang Hwang; Sun-Ouck Kim
Journal:  Asian J Androl       Date:  2011-04-04       Impact factor: 3.285

3.  Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.

Authors:  E Y Oh; S K Bae; J W Kwon; M You; D C Lee; M G Lee
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

Review 4.  [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology].

Authors:  A J Becker; S Uckert; C G Stief
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

5.  Erectile dysfunction and its management in patients with diabetes mellitus.

Authors:  Giuseppe Defeudis; Daniele Gianfrilli; Chiara Di Emidio; Riccardo Pofi; Dario Tuccinardi; Andrea Palermo; Andrea Lenzi; Paolo Pozzilli
Journal:  Rev Endocr Metab Disord       Date:  2015-10-26       Impact factor: 6.514

6.  Udenafil: efficacy and tolerability in the management of erectile dysfunction.

Authors:  Sung Gu Kang; Je Jong Kim
Journal:  Ther Adv Urol       Date:  2013-04

7.  Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.

Authors:  Bo-Hyung Kim; Hyeong-Seok Lim; Jae-Yong Chung; Jung-Ryul Kim; Kyoung Soo Lim; Dong-Ryul Sohn; Joo-Youn Cho; Kyung-Sang Yu; Sang-Goo Shin; Jae-Seung Paick; In-Jin Jang
Journal:  Br J Clin Pharmacol       Date:  2008-03-03       Impact factor: 4.335

8.  ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.

Authors:  Kyung-Hee Kim; Hyung-Kwan Kim; In-Chang Hwang; Seung-Pyo Lee; Hyun-Jai Cho; Hyun-Jae Kang; Yong-Jin Kim; Dae-Won Sohn
Journal:  Trials       Date:  2013-06-22       Impact factor: 2.279

9.  An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies.

Authors:  Gong Chen; Huanchen Wang; Howard Robinson; Jiwen Cai; Yiqian Wan; Hengming Ke
Journal:  Biochem Pharmacol       Date:  2008-02-12       Impact factor: 5.858

10.  Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.

Authors:  Huanchen Wang; Mengchun Ye; Howard Robinson; Sharron H Francis; Hengming Ke
Journal:  Mol Pharmacol       Date:  2007-10-24       Impact factor: 4.436
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.